US EditionWhy Is United Therapeutics Stock Rallying On Tuesday? - United Therapeutics (NASDAQ:UTHR)
Summary by Benzinga
4 Articles
4 Articles
Why Is United Therapeutics Stock Rallying On Tuesday? - United Therapeutics (NASDAQ:UTHR)
United Therapeutics Corporation (NASDAQ:UTHR) released data on Tuesday from its TETON-2 study evaluating the use of nebulized Tyvaso (treprostinil) Inhalation Solution for idiopathic pulmonary fibrosis (IPF). The study met its primary efficacy endpoint of demonstrating improvement in absolute forced vital capacity (FVC) relative to placebo. FVC is a standard pulmonary function test. Tyvaso demonstrated superiority over placebo for the change in …
·New York, United States
Read Full Article
United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis - Life Sciences British Columbia
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. - United Therapeutics announces TETON-2, evaluating Tyvaso, a treatment for (IDF).
Coverage Details
Total News Sources4
Leaning Left1Leaning Right0Center1Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
